Integra LifeSciences Reports Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Integra LifeSciences (IART) Reports In-Line Q2 EPS, Revenues Miss; Boosts FY18 EPS/Revenue Mid-Point Outlooks Below Consensus
July 25, 2018 6:11 AM EDTIntegra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.60, in-line with the analyst estimate of $0.60. Revenue for the quarter came in at $366.2 million versus the consensus estimate of $368.25 million.
Revenue Increased 29.8% to $366.2 million; Organic Revenue Increased 3.4% Reported EPS of $0.14; Adjusted EPS of $0.60Raises Low-End of Full-Year Total Revenue and EPS GuidanceSuccessfully Exits First Wave of Codman Transition Services AgreementsSecond Quarter 2018 Consolidated Results
Reported revenue was $366.2 million, an increase of 29.8% compared to the second quarter of 2017;... More